BI-1206 +/- rituximab & acalabrutinib

26 Aug 2025 — BioInvent International AB (Nasdaq Stockholm: BINV) announced a portfolio optimization to prioritize its lead immuno-oncology assets BI-1808 (first-in-class anti-TNFR2 antibody) and BI-1206 (FcγRIIB-blocking antibody), citing strong/encouraging clinical activity and good tolerability in ongoing Phase 1/2a programs. The company will pause Phase 1 development of BI-1910 and BI-1607, and continue BT-001 via an investigator-led trial with Transgene. BioInvent plans to initiate a Phase 2a study of BI-1206 plus pembrolizumab in first-line metastatic NSCLC in H2 2025.

Key upcoming catalysts: H2 2025 Phase 2a data for BI-1808 + pembrolizumab in solid tumors; H1 2026 additional BI-1206 triplet data in NHL and BI-1808 data in CTCL; H2 2026 first readout from the BI-1206 + pembrolizumab Phase 2a (NSCLC and uveal melanoma cohorts). Subject to union negotiations, BioInvent will reduce workforce by ~25 positions and expects current cash to fund operations into Q1 2027, beyond multiple data readouts.